{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/cellulitis-acute/prescribing-information/erythromycin/","result":{"pageContext":{"chapter":{"id":"07828388-33ed-5e04-90b7-28a76fa26c6e","slug":"erythromycin","fullItemName":"Erythromycin","depth":2,"htmlHeader":"<!-- begin field ba20b48d-a5d6-464f-b4ae-aadb00c001e1 --><h2>Erythromycin</h2><!-- end field ba20b48d-a5d6-464f-b4ae-aadb00c001e1 -->","summary":"","htmlStringContent":"<!-- begin item 6a4f1288-220e-4743-aea8-aadb00c001a2 --><!-- end item 6a4f1288-220e-4743-aea8-aadb00c001a2 -->","topic":{"id":"c0841d82-0a64-5b27-81dc-9a825d85f1bf","topicId":"6db61277-29ef-49cc-bad1-d0d78d0afc10","topicName":"Cellulitis - acute","slug":"cellulitis-acute","lastRevised":"Last revised in January 2021","chapters":[{"id":"84376fdb-da2b-561d-bb40-28b5b1a7e975","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"bdf35905-533d-5cb1-bd18-9c1575427a25","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"d6c8c4bd-9395-5840-83c7-67ddfeabdf85","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"59d003f6-dd50-5136-b5c2-c2ea4e4b6f01","slug":"changes","fullItemName":"Changes"},{"id":"f79ca51e-9432-56b1-95de-92ed6133be2b","slug":"update","fullItemName":"Update"}]},{"id":"05002b30-8200-5ccf-b9da-7c96acdb65bd","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"fefb70b6-1d32-5e70-afc6-291fa40b3137","slug":"goals","fullItemName":"Goals"},{"id":"cf84220a-f381-5ca1-aa76-ffb99c4959f6","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"aa32cbb7-29d6-58b6-bcde-7702767672ec","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7e039433-2afe-5980-93f0-c20c41976610","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d1411fdd-dc83-5f20-9fa4-ad67b69c195a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"ce40a600-51e8-5b3a-86c2-d127f03c16eb","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"ff60c523-3d6f-5766-8508-98e8cdcf08f5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8e8cfe4a-13f2-573c-ab45-7231016746c4","slug":"definition","fullItemName":"Definition"},{"id":"2b7befe3-0fef-5d4e-b00d-bad6742fb93c","slug":"causes","fullItemName":"Causes"},{"id":"96971948-f52b-561c-84f8-8600f3eff2d4","slug":"prevalence","fullItemName":"Prevalence"},{"id":"4749dc8a-3f24-5e65-a0a3-5d7665ef3085","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"ad3d41f6-595b-505c-b020-918f0e086d3f","slug":"complications","fullItemName":"Complications"},{"id":"82ccb916-06d4-5b29-91e4-90005f3db942","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"7305e6df-9b2c-5584-9412-54564432e382","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8625eea6-53ec-5348-befa-a609ea64590f","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"273b1216-536e-59b4-8c39-547a97824ffa","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"68b86e3a-ee13-5ccd-9df0-a5c70c553251","fullItemName":"Management","slug":"management","subChapters":[{"id":"195394ca-067a-5cf3-bc4d-52a189d2cba6","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"4426193a-52c1-59b9-9222-77fb7169a3d1","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"78de19b8-8e80-551f-8112-456ce2e25bb0","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"73060223-dd90-59da-bae3-c706b5d24298","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"83f47301-e112-5f78-a79a-5c03a9de9537","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"b7240858-fbcc-5f20-8dcd-19f0b7221ac4","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"07828388-33ed-5e04-90b7-28a76fa26c6e","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"4600d0c1-4cd1-51ee-87a0-b660f0fa2165","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"0c0b7a3f-11e4-5b00-bd21-b66e49f9ad77","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"29987f8b-20b6-5c1f-8d23-183b415a04fb","slug":"analgesia","fullItemName":"Analgesia"}]},{"id":"4b09dc1a-8268-50d6-a164-227a73b3556e","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"d49b86e1-77b2-58e6-82c0-ea0aa7ee74ed","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"fe910063-69df-5218-bb78-36f5863db2a1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"129f5233-2934-55ad-a561-4eb37861dc10","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"74d5b6b4-ef9d-5fc4-b41b-656b81a7ded8","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"44402335-ffeb-5e14-9e77-bb8278ef43d6","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"04d7d640-f586-53d9-ac59-804c10dd593d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"c50af1ff-f157-5023-92b4-aa07b1c28d76","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"4426193a-52c1-59b9-9222-77fb7169a3d1","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"400c7d44-7d66-5fad-a198-4e48465a2a16","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 18cc264a-bc82-44bb-8eaf-aadb00c10c4f --><h3>What are the contraindications and cautions for erythromycin?</h3><!-- end field 18cc264a-bc82-44bb-8eaf-aadb00c10c4f -->","summary":"","htmlStringContent":"<!-- begin item 8cdb55bd-f571-4d42-8f68-aadb00c10c06 --><!-- begin field bf4e412d-d6a0-4187-b9aa-aadb00c10c4f --><ul><li><strong>Do not prescribe erythromycin to people: </strong><ul><li>With acute porphyrias.</li><li>Taking medicines that interact with erythromycin (for example, simvastatin, mizolastine, domperidone, cisapride, pimozide, ergotamine, dihydroergotamine).</li><li>With a history of QT interval prolongation or ventricular cardiac arrhythmia.</li><li>With conditions that predispose to QT interval prolongation such as electrolyte disturbances and people taking drugs that prolong the QT interval </li></ul></li><li><strong>Prescribe erythromycin with caution to people with:</strong><br><ul><li>Myasthenia gravis.</li><li>Hepatic impairment.</li><li>Renal impairment — the maximum daily dose in adults with severe renal impairment is 1500 mg daily. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">ABPI, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Joint Formulary Committee, 2019</a>] ​​​​​​​[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">MHRA, 2020</a>]</p><!-- end field bf4e412d-d6a0-4187-b9aa-aadb00c10c4f --><!-- end item 8cdb55bd-f571-4d42-8f68-aadb00c10c06 -->","subChapters":[]},{"id":"1999f117-21e9-5a2b-b504-24ffca78b5bf","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 345bd865-02f2-494e-8d6c-aadb00c118d7 --><h3>What are the possible adverse effects of erythromycin?</h3><!-- end field 345bd865-02f2-494e-8d6c-aadb00c118d7 -->","summary":"","htmlStringContent":"<!-- begin item 5ef71bdc-9d2f-4901-ae12-aadb00c118a8 --><!-- begin field 0b50642d-a9a5-4266-81db-aadb00c118d7 --><ul><li><strong>Gastrointestinal</strong> (GI) — diarrhoea, GI discomfort/disorders, nausea, vomiting (common or very common); consipation (uncommon).<ul><li><strong>Rare or very rare:</strong> antibiotic associated colitis.</li></ul></li><li><strong>Cardiovascular</strong> — QTc interval prolongation, torsades de pointes, palpitations and cardiac rhythm disorders including ventricular tachyarrhythmias (uncommon).</li><li><strong>Hepatobiliary — </strong>cholestatic hepatitis, jaundice, hepatic disfunction, hepatomegaly, hepatic failure, hepatocellular hepatitis</li><li><strong>Skin and subcutaneous tissues</strong> — skin reactions (common or very common); Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme (uncommon); acute generalised exanthematous pustulosis (AGEP) (frequency unknown).</li><li><strong>Other common adverse effects include:</strong><ul><li>Dizziness</li><li>Headache</li><li>Hearing impairment</li><li>Vasodilation</li><li>Vision disorders.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">ABPI, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 0b50642d-a9a5-4266-81db-aadb00c118d7 --><!-- end item 5ef71bdc-9d2f-4901-ae12-aadb00c118a8 -->","subChapters":[]},{"id":"93a426b4-3522-5072-a0ad-4737d4b191dd","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field c28d8f83-8d1e-4c92-b2ef-aadb00c12806 --><h3>What are the possible drug interactions of erythromycin?</h3><!-- end field c28d8f83-8d1e-4c92-b2ef-aadb00c12806 -->","summary":"","htmlStringContent":"<!-- begin item 0f91e8f8-35fe-491f-88e5-aadb00c127e1 --><!-- begin field 7c4b8dfd-df44-4919-97b4-aadb00c12806 --><ul><li><p><strong>Drug interactions for erythromycin include:</strong></p><ul><li><strong>Aminophylline</strong> — aminophylline can cause hypokalaemia (potentially increasing the risk of torsade de pointes) when given with erythromycin. Theophylline clearance may also be reduced if given concurrently with erythromycin. Monitor theophylline levels after 48 hours and adjust the dose accordingly. Monitor potassium concentrations closely and the effects of oral erythromycin to ensure they are adequate. Consider giving an alternative antibiotic. </li><li><strong>Calcium channel blockers </strong>(amlodipine, diltiazem) — erythromycin possibly inhibits the metabolism of calcium channel blockers, increasing the risk of adverse effects, such as hypotension. Monitor for adverse effects (for example, bradycardia, hypotension, headache, oedema) and reduce the calcium-channel blocker dose as necessary.</li><li><strong>Rifampicin</strong> — may induce the metabolism of clarithromycin, resulting in sub-therapeutic levels.<ul><li>If concurrent use is necessary, monitor erythromycin efficacy closely.</li></ul></li><li><strong>Carbamazepine </strong>— erythromycin can increase carbamazepine levels, causing carbamazepine toxicity (which may present as nausea and vomiting, ataxia, and drowsiness).<ul><li>Avoid concurrent use, unless carbamazepine levels can be monitored closely. amino</li></ul></li><li><strong>Ciclosporin</strong> — levels are greatly increased by erythromycin. Monitor concentrations and effects (for example, renal function) more frequently if erythromycin is started or stopped. Adjust the ciclosporin dose as required. </li><li><strong>Cisapride, domperidone</strong> — levels may be raised, increasing the risk of potentially life-threatening arrhythmias (torsade de pointes). Concurrent use is contraindicated.</li><li><strong>Colchicine </strong>— erythromycin possibly increases the risk of colchicine toxicity.<ul><li>Stop or reduce the dose of colchicine.</li><li>Avoid concomitant use in renal or hepatic impairment.</li></ul></li><li><strong>Drugs that prolong the QT interval</strong> (such as amiodarone, amisulpride, fluconazole, sildenafil, mizolastine, hydroxyzine) — macrolides can also prolong the QT interval, increasing the risk of arrhythmias (such as Torsades de pointes).<ul><li>Concurrent use of drugs that prolong the QT interval is not recommended.</li></ul></li><li><strong>Drugs that cause hypokalaemia</strong> (such as diuretics, corticosteroids, short-acting beta-2 agonists) — hypokalaemia is a risk factor for QT prolongation. Monitor potassium levels closely. </li><li><strong>Digoxin</strong> — erythromycin may increase the concentration of digoxin. <ul><li>Monitor digoxin concentration.</li></ul></li><li><strong>Ergot alkaloids </strong>(such as ergotamine and dihydroergotamine)<strong> </strong>— concurrent use with erythromycin may result in acute ergot toxicity. <ul><li>Concurrent use is contraindicated.</li></ul></li><li><strong>Protease inhibitors</strong> (ritonavir, saquinavir) — erythromycin levels may be increased. Monitor for adverse effects. </li><li><strong>Statins </strong>— there is an increased risk of myopathy (due to cytochrome P450 enzyme CYP3A4 inhibition) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">MHRA, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">MHRA, 2014</a>].   <ul><li>For simvastatin (potent CYP3A4 inhibitor) — concurrent use is contraindicated. If erythromycin treatment cannot be avoided, stop treatment with simvastatin during the course of the treatment.</li><li>For atorvastatin (moderate CYP3A4 inhibitor) — avoid concurrent use if possible. If erythromycin treatment cannot be avoided, stop treatment with simvastatin during the course of the treatment or prescribe the lowest starting dose of atorvastatin (that is 10 mg) and do not exceed 20 mg atorvastatin daily. Advise the person to seek medical advice if they experience symptoms of myopathy (for example muscle pain, tenderness, or weakness).</li><li>For pravastatin — prescribe erythromycin with caution, and advise the person to report any muscle pain, tenderness, or weakness.</li></ul></li><li><strong>Theophylline </strong>— erythromycin possibly increases the plasma concentration of theophylline.<ul><li>Monitor theophylline levesl after 48 hours and adjust the theophylline dose if necessary.</li></ul></li><li><strong>Quetiapine </strong>— erythromycin increases the plasma concentration of quetiapine and both drugs are associated with QT interval prolongation.<ul><li>Concurrent use is contraindicated, but if necessary, monitor for quetiapine adverse effects (for example, somnolence, dry mouth, tachycardia) and reduce the dose if needed.</li></ul></li><li><strong>Rivaroxaban </strong>— erythromycin may increase levels of rivaroxaban, increasing the risk of bleeding. </li><li><strong>Warfarin </strong>— erythromycin may cause a minor increase in warfarin effects. <ul><li>Consider increased monitoring of the international normalized ratio (INR) when both drugs are used (particularly in elderly people), and adjust the warfarin dose accordingly. </li></ul></li></ul></li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are <em>not</em> required during or after a course of erythromycin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">FSRH, 2017</a>].<ul><li>However, advise women on the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the section on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li><li><strong>For a complete list of possible drug interactions for erythromycin, </strong>see the <a href=\"http://scribe.clarity.co.uk/www.medicines.org.uk/emc\" data-hyperlink-id=\"40ec65d5-2d3d-46c6-a3a8-a98f01110425\">electronic Medicines Compendium</a> (eMC) or the <a href=\"https://bnf.nice.org.uk/\" data-hyperlink-id=\"cf6a8caf-9ccd-4adf-9777-a98f0111044b\">British National Formulary</a> (BNF).</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">MHRA, 2020</a>]</p><!-- end field 7c4b8dfd-df44-4919-97b4-aadb00c12806 --><!-- end item 0f91e8f8-35fe-491f-88e5-aadb00c127e1 -->","subChapters":[]},{"id":"3f44bc02-3faa-500a-9bbd-b63942e38c51","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field d41fa59f-e71a-4418-9592-aadb00c1349e --><h3>Can erythromycin be used during pregnancy and breastfeeding?</h3><!-- end field d41fa59f-e71a-4418-9592-aadb00c1349e -->","summary":"","htmlStringContent":"<!-- begin item 5166af5c-b10c-473d-a5d9-aadb00c13479 --><!-- begin field 4b45ed91-6882-4b91-8658-aadb00c1349e --><h4>Pregnancy</h4><ul><li>The use of erythromycin in pregnancy is not known to be harmful — the considerable data for macrolides as a class, and for erythromycin specifically, do not suggest an increased overall risk of congenital malformation or of cardiac malformations specifically [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Joint Formulary Committee, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">UKTIS, 2019</a>]. </li><li>However, the manufacturer states that [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">ABPI, 2019</a>]: <ul><li>Observational studies in humans have reported cardiovascular malformations after exposure to medicinal products containing erythromycin during early pregnancy.</li><li>There have been reports that maternal macrolide antibiotics exposure within 7 weeks of delivery may be associated with a higher risk of infantile hypertrophic pyloric stenosis (IHPS).</li></ul></li></ul><h4>Breastfeeding</h4><ul><li>Erythromycin is excreted in breast milk in small amounts and it is not known to be harmful [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Joint Formulary Committee, 2019</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">LactMed, 2019</a>].<ul><li>Monitor the infant for irritability and possible effects on the gastrointestinal flora, such as diarrhea, candidiasis (thrush, nappy rash). </li></ul></li><li>However, the manufacturer advises exercising caution due to reports of infantile hypertrophic pyloric stenosis in breast-fed infants [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">ABPI, 2019</a>]. </li></ul><!-- end field 4b45ed91-6882-4b91-8658-aadb00c1349e --><!-- end item 5166af5c-b10c-473d-a5d9-aadb00c13479 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}